Correction for “ Interleukin 1 receptor - associated kinase 1 ( IRAK 1 )

MICROBIOLOGY Correction for “Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma,” by Dongmei Yang, Wuguo Chen, Jie Xiong, Carly J. Sherrod, David H. Henry, and Dirk P. Dittmer, which appeared in issue 44, November 4, 2014, of Proc Natl Acad Sci USA (111:E4762–E4768; first published October 23, 2014; 10.1073/ pnas.1405423111). The authors note that on page E4765, left column, third full paragraph, the text should instead appear as “From a statistical point of view, all the PEL-specific SNVs represent candidate driver mutations and deserve experimental follow-up, most notably VBP1 and WDR13, which are abundantly transcribed in PEL. We prioritized IRAK1 because IRAK inhibitors have entered phase I human clinical trials. Fifty-five previously identified, noncoding SNVs in the IRAK1 locus were not conserved among PEL; only the IRAK1 mutation was. The IRAK1 mutation is a common polymorphism, as recorded in various SNV databases. The odds ratio for association of this SNV with PEL is estimated at 8.4. . .686.5 (95% CI). Because we only had two matched normal and tumor samples, we cannot claim that any of the PEL-specific SNVs represent somatic events in addition to PEL-defining polymorphisms.”